DexCom, Inc. (NASDAQ:DXCM – Get Free Report) CEO Kevin R. Sayer sold 32,498 shares of the stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the completion of the transaction, the chief executive officer now directly owns 372,029 shares of the company’s stock, valued at approximately $26,183,401.02. The trade was a 8.03 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
DexCom Stock Performance
DexCom stock opened at $70.69 on Friday. The company has a market capitalization of $27.62 billion, a PE ratio of 49.43, a P/E/G ratio of 2.30 and a beta of 1.28. The company has a 50 day moving average price of $83.99 and a 200-day moving average price of $76.89. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00.
DexCom (NASDAQ:DXCM – Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, equities analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.
Hedge Funds Weigh In On DexCom
Analyst Upgrades and Downgrades
A number of brokerages recently commented on DXCM. Morgan Stanley increased their price target on shares of DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a report on Friday, February 14th. Wells Fargo & Company reissued an “overweight” rating on shares of DexCom in a research note on Saturday, March 8th. Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Canaccord Genuity Group raised their price objective on shares of DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. Finally, Citigroup raised their price objective on shares of DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research note on Tuesday, March 4th. Four investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $99.82.
Read Our Latest Report on DXCM
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
Further Reading
- Five stocks we like better than DexCom
- Top Biotech Stocks: Exploring Innovation Opportunities
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Are Penny Stocks a Good Fit for Your Portfolio?
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- How Investors Can Find the Best Cheap Dividend Stocks
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.